Phenylpiracetam Hydrazide

guinea pig

Also seen as: fonturacetam hydrazide, phenylpiracetam-hydrazide, PPH

The Dose Guy’s verdict

Sep 1, 2026
0 sources

Zero. Not thin data, not old data, zero. No published study of any kind exists for phenylpiracetam hydrazide. It is sold on the reputation of phenylpiracetam, which at least has animal pharmacology and a WADA ban behind it. Whether swapping in a hydrazide group preserves the parent’s profile is genuinely unknown. It might work the same. It might not. If you want what the parent offers, run the parent until somebody generates real data on this derivative.

Would I take it?No data of its own. The parent is the safer bet.

What it is

A structural analog of phenylpiracetam carrying a hydrazide modification. The compound began appearing in vendor catalogs around the time Phenotropil production stopped in Russia and phenylpiracetam supply thinned. Whether the modification was driven by chemistry, regulatory positioning, or market opportunity is unclear. What is clear is that nobody has published a single study characterizing what it does to the pharmacology.

Phenylpiracetam hydrazide is a research chemical in the purest sense: a chemical people run on themselves with no research behind it. The parent compound at least has the WADA ban, the dopamine-transporter binding data, and Russian clinical use. This derivative has none of that. The assumption that structural similarity equals functional similarity is common in this space and has been wrong before.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The published literature contains nothing on phenylpiracetam hydrazide. Not a gap in the evidence, an absence.

No mechanism study, no animal study, no human study, no case report. Phenylpiracetam hydrazide does not appear in the biomedical literature at all.as of Aug 2026

Realistic protocols

There is no evidence to build a protocol from. The community runs it at roughly 50 to 150 mg orally, treating it like a slightly different version of the parent and applying the same as-needed pattern: a dose on heavy work days, not daily. Whether this dosing is correct, safe, or even in the right range is unknown because no pharmacokinetic or dose-finding study has ever been done. If you run it: go low, go short, and do not assume the parent compound’s profile transfers intact. If you want that experience with at least some evidence trail, run the parent.

Side effects

No safety data of any kind exists for phenylpiracetam hydrazide:

anecdotalUsers report a profile similar to phenylpiracetam, stimulating with a clean focus push, but this is assumption dressed as observation.

unknownEvery side effect is unknown. A structural modification can change toxicity, receptor binding, and metabolism in ways that cannot be predicted from the parent compound alone.

Where to buy

No live listings from tracked vendors right now.